Canada markets close in 4 hours 36 minutes
  • S&P/TSX

    20,997.65
    +337.66 (+1.63%)
     
  • S&P 500

    4,650.77
    +83.77 (+1.83%)
     
  • DOW

    34,985.12
    +501.40 (+1.45%)
     
  • CAD/USD

    0.7843
    +0.0018 (+0.24%)
     
  • CRUDE OIL

    68.45
    +2.27 (+3.43%)
     
  • BTC-CAD

    75,138.71
    +1,675.89 (+2.28%)
     
  • CMC Crypto 200

    1,502.26
    +33.18 (+2.26%)
     
  • GOLD FUTURES

    1,788.30
    +11.80 (+0.66%)
     
  • RUSSELL 2000

    2,248.86
    +49.96 (+2.27%)
     
  • 10-Yr Bond

    1.4890
    +0.0460 (+3.19%)
     
  • NASDAQ

    15,804.54
    +266.85 (+1.72%)
     
  • VOLATILITY

    22.83
    -4.36 (-16.04%)
     
  • FTSE

    7,161.10
    +101.65 (+1.44%)
     
  • NIKKEI 225

    27,935.62
    +113.86 (+0.41%)
     
  • CAD/EUR

    0.6922
    +0.0025 (+0.36%)
     

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amarin Corporation plc (AMRN) on Behalf of Investors

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BENSALEM, Pa., October 28, 2021--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN) investors concerning the Company’s possible violations of federal securities laws.

On March 30, 2020, Amarin announced that "the United States District Court for the District of Nevada[] rul[ed] in favor of the generic companies in the company’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s VASCEPA® (icosapent ethyl) capsule franchise." On this news, Amarin’s share price fell $9.58, or approximately 70.5%, to close at $4.00 per share on March 31, 2020, thereby injuring investors.

On June 21, 2021, investors learned that the Supreme Court rejected the Company’s bid to revive its Vascepa patents. On this news, Amarin’s share price fell 5.2%, to close at $4.70 per share on June 21, 2021, further injuring investors.

If you purchased Amarin securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005913/en/

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting